Precigen Inc
Company Profile
Business description
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Contact
20374 Seneca Meadows Parkway
GermantownMD20876
USAT: +1 301 556-9900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
47
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
stocks
Our top ASX picks in every sector
stocks
Which of the 3 giant AI IPOs should you buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,810.60 | 89.10 | -1.00% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 25,024.48 | 269.55 | -1.07% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 52,780.13 | 959.55 | -1.79% |
| NZX 50 Index | 12,865.18 | 39.31 | 0.31% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,612.20 | 72.80 | -0.84% |
| SSE Composite Index | 3,933.16 | 15.39 | -0.39% |